Danaher Corporation (DHR) has been benefiting from strength in its bioprocessing business, driven by an increase in demand for consumables from large pharmaceutical customers in North America, Europe and Southeast Asia. In the first quarter of 2025, orders in the bioprocessing business increased for the seventh consecutive quarter. For 2025, Danaher anticipates core revenues from the bioprocessing business to increase in high-single-digits on a year-over-year basis.Also, solid momentum in the discovery and ...